Effect of Eplerenone on Endothelial Function in Patients With Stable Coronary Heart Disease
Launched by UNIVERSITY OF ZURICH · Jan 26, 2007
Trial Information
Current as of June 26, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • Male patients (\> 30 years of age) with history of coronary artery disease (documented by coronary angiogram, nuclear imaging, positive stress test)
- • Stable cardiovascular medication for at least 4 months Evaluation of the patients will take place at the Department of Internal Medicine, Cardiology, University Hospital Zurich.
- Exclusion criteria:
- • Evidence for myocardial infarction, unstable angina, stroke within 3 months prior to study entry
- • coronary intervention/re-vascularisation procedure within 3 months prior to study entry
- • long acting nitrates
- • uncontrolled arterial hypertension, defined as RR\>160/90 mmHg
- • congestive heart failure (\> NYHA I)
- • Ejection fraction \<50%
- • AV-Block\>I˚
- • creatinine clearance \<50 mL/min
- • insulin-dependent diabetes mellitus
- • type 2 diabetes with microalbuminuria
- • age \< 30 years
- • anemia (Hb\<10 g/dl)
- • malignancy chronic infection
- • smoking
- • serum potassium \>5.5 meq/L
- • drug abuse
- • potassium supplements or potassium-sparing diuretics (amiloride, spironolactone, or triamterene)
- • concomitant use of strong inhibitors of CYP450 3A4 (e.g., ketoconazole, itraconazole)
- • known history of Cushing disease or Morbus Addisons or diseases of the thyroid gland
About University Of Zurich
The University of Zurich, a leading institution in research and education, is dedicated to advancing medical knowledge and improving patient care through innovative clinical trials. With a robust framework for conducting high-quality research, the university collaborates with multidisciplinary teams of experts to explore cutting-edge therapeutic approaches and interventions. Its commitment to ethical standards and patient safety ensures that all clinical trials are conducted with the utmost integrity, aiming to contribute valuable insights to the medical community and enhance health outcomes globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zurich, Zh, Switzerland
Patients applied
Trial Officials
Frank Ruschitzka, Prof MD
Principal Investigator
University Hospital Zurich, Division of Cardiology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials